drugset / Trial / NCT05318937
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
Timeline
- Start
- 2022-06-06
- Primary completion
- 2024-01-17
- Completion
- 2024-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalzanemdor | Small molecule | 1.2 mg | Oral |